title: The 677 C-T methylenetetrahydrofolate reductase mutation does not predict increased maternal homocysteine during pregnancy.
abstract: OBJECTIVE
  To test the hypothesis that, regardless of the presence of the 677 C-T methylenetetrahydrofolate reductase (MTHFR) mutation, maternal homocysteine concentrations will not be significantly different in women who are taking prenatal vitamins containing folic acid, and to test this relationship in preeclampsia because homocysteine concentrations are higher in preeclamptic pregnancies.
  
  
  METHODS
  Fifty-seven pregnant white women (control and preeclamptic) with and without the 677 C-T MTHFR mutation were studied. Total plasma homocysteine and plasma folic acid were analyzed.
  
  
  RESULTS
  Homocysteine concentrations were not different by MTHFR genotype (wild type 677 CC 8.7 +/- 5.6 microM versus mutant 677 TT 9.0 +/- 5.7 microM, P =.84) in preeclamptic or normal pregnancies. However, mean homocysteine concentrations were significantly increased in preeclamptic pregnancies compared with those in normal pregnancies (10.6 +/- 7.3 microM versus 7.2 +/- 3.0 microM, P <.03) as previously reported.
  
  
  CONCLUSIONS
  The 677 C-T MTHFR polymorphism does not significantly affect maternal homocysteine concentrations in most women taking prenatal vitamins including women with preeclampsia. The increase in plasma folic acid likely affects maternal homocysteine more than the MTHFR genotype. If homocysteine is considered a thrombophilia risk factor, the concentration of the amino acid and not a particular genotype should be determined.
authors.affiliation: Department of Obstetrics, Gynecology, and Reproductive Sciences, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA. rsirwp@mail.magee.edu
authors.forename: Robert W
authors.initials: RW
authors.lastname: Powers
authors.forename: Michael S
authors.initials: MS
authors.lastname: Dunbar
authors.forename: Marcia J
authors.initials: MJ
authors.lastname: Gallaher
authors.forename: James M
authors.initials: JM
authors.lastname: Roberts
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D019587:Dietary Supplements; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage / Q000097:blood; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000097:blood / Q000235:genetics*; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000235:genetics*; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000097:blood*; D012189:Retrospective Studies
chemical_list: D006710:Homocysteine; D005492:Folic Acid; D000587:Oxidoreductases Acting on CH-NH Group Donors; D042965:Methylenetetrahydrofolate Reductase (NADPH2)